LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.28 2.4

Buy Sell

Overview

Share price change

24h

Current

Min

1.22

Max

1.32

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-34M 68M
Previous open	-1.12
Previous close	1.28

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 lut 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

19 lut 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 lut 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 lut 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 lut 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 lut 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 lut 2026, 23:37 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 lut 2026, 23:34 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 lut 2026, 23:34 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 lut 2026, 23:33 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 lut 2026, 23:33 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 lut 2026, 22:13 UTC

Market Talk

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 lut 2026, 22:08 UTC

Earnings

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 lut 2026, 22:07 UTC

Earnings

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 lut 2026, 22:06 UTC

Earnings

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 lut 2026, 22:05 UTC

Earnings

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 lut 2026, 22:05 UTC

Earnings

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 lut 2026, 22:04 UTC

Earnings

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 lut 2026, 22:04 UTC

Earnings

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 lut 2026, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

19 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 lut 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19 lut 2026, 21:43 UTC

Earnings

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 lut 2026, 21:42 UTC

Acquisitions, Mergers, Takeovers

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 lut 2026, 21:42 UTC

Earnings

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 lut 2026, 21:41 UTC

Earnings

Correct: St Barbara 1H Net Loss A$249,000

19 lut 2026, 21:40 UTC

Earnings

St Barbara 1H Net Loss A$249 Million

19 lut 2026, 21:39 UTC

Earnings

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 lut 2026, 21:37 UTC

Earnings

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 lut 2026, 21:37 UTC

Earnings

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Rating Consensus

By TipRanks

Sell

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.